Examples of 'belatacept' in a sentence
Meaning of "belatacept"
Belatacept is a noun that refers to a medication used to prevent organ rejection in certain transplant patients
Show more definitions
- A fusion protein, similar to abatacept, used to improve graft survival after transplantation.
How to use "belatacept" in a sentence
Basic
Advanced
belatacept
Belatacept is known to cross the placenta of animals.
Therapeutic monitoring of belatacept is not required.
Plasmapheresis may accelerate removal of belatacept.
There are no data on use of belatacept and effect on fertility in humans.
Studies in rats have shown excretion of belatacept in milk.
Belatacept was shown to cross the placenta in rats and rabbits.
It contains the active substance belatacept.
Belatacept should not be used in pregnant women unless clearly necessary.
There are no adequate data from use of belatacept in pregnant women.
Belatacept has a minor influence on the ability to drive and use machines.
The active substance is belatacept.
Allergic reactions related to belatacept use have been reported in the clinical studies.
There were no reports of anaphylaxis on belatacept.
Belatacept is another novel molecule which is being tested for use in renal transplantation.
Patient and graft survival were similar between belatacept and ciclosporin.
See also
The pharmacokinetics of belatacept in renal transplant patients and healthy subjects appeared to be comparable.
Adequate treatment of latent tuberculosis infection should be instituted prior to belatacept use.
The pharmacokinetics of belatacept in de novo kidney transplant patients and healthy subjects are comparable.
The safety and efficacy of retreatment with belatacept has not been studied.
Patients should be evaluated for tuberculosis and tested for latent infection prior to initiating belatacept.
Belatacept is not expected to interrupt the enterohepatic recirculation of MPA.
This observation was more pronounced with the higher than recommended dose of belatacept.
Belatacept is produced by recombinant DNA technology in a mammalian cell expression system.
EBV serology should be ascertained before starting administration of belatacept.
Belatacept is a fusion protein produced in Chinese hamster ovary cells by recombinant DNA technology.
NULOJIX contains the active substance belatacept which belongs to a group of medicines called immunosuppressants.
In certain embodiments, the second agent is belatacept.
In rats, belatacept had no undesirable effects on male or female fertility.
Patients do not require pre-medication prior to administration of belatacept.
The trough concentration of belatacept was consistently maintained up to 5 years post-transplant.
After reconstitution, each ml of concentrate contains 25 mg belatacept.
Anti-belatacept antibody development was not associated with altered clearance of belatacept.
Infusion-related reactions have been reported with belatacept administration in clinical studies.
Within the belatacept clinical program, there were 2 patients diagnosed with PML.
Abatacept is the basis for the second-generation belatacept currently being tested in clinical trials.
In rats, belatacept had no undesirable effects on male or female fertility see section 5.3.
Therefore, the recommended dose of belatacept is the LI dosage regimen.
The belatacept amino acid sequence was used as input into the NetOGlyc3.1 software online.
In both studies, mean GFR following AR was similar in belatacept and ciclosporin treated patients.
These belatacept dosing regimens differed from those studied in renal transplant recipients see section 5.1.
Volume of the reconstituted solution required ( ml ) equals total belatacept dose in mg divided by 25.
It is unknown whether belatacept is excreted in human milk see section 5.3.
The black square represents the parent CTLA4-Ig abatacept, and the black open circle represents belatacept.
Table 1, Dose of belatacept for renal transplant recipients.
NULOJIX 250 mg powder for concentrate for solution for infusion belatacept.
PTLD occurred at a higher rate in both belatacept treatment groups versus ciclosporin see section 4.4.
Transplant recipients who are EBV seronegative or serostatus unknown should not receive belatacept see section 4.3.
The result for belatacept wild-type is shown in Figure 1C.
The known N-linked and O-linked glycosylation sites for belatacept are shown in Figure 1A.
As a result, belatacept blocks CD28 mediated co-stimulation of T cells inhibiting their activation.
